Functional reassessment of PAX6 single nucleotide variants by in vitro splicing assay


Nucleotide variants that disrupt normal splicing might be the cause of a large number of diseases. Nevertheless, because of the complexity of splicing regulation, it is not always possible to accurately predict the effect of nucleotide sequence changes on splicing events and mRNA structure. Thereby, a number of newly identified nucleotide variants are falsely classified as VUS (a variant of uncertain significance). In the present study we used the minigene assay to analyze the functional consequences of six intronic (c.142−5T>G, c.142−14C>G, c.142−64A>C, c.141+4A>G, c.1032+ 6T>G, c.682+4delA), one missense (c.140A>G) and one synonymous (c.174C>T) variants in the PAX6 gene found in patients with congenital aniridia. We revealed that all except one (c.142−64A>C) variants lead to the disruption of normal splicing patterns resulting in premature termination codon formation followed by mRNA degradation through the nonsense mediated decay pathway. This produces a null allele of the PAX6 gene. That allowed us to reclassify the analyzed variants as loss-of-function and to establish their functional role.


Congenital aniridia is a rare autosomal dominant panocular disorder. Loss-of-function nucleotide variants and haploinsufficiency of the PAX6 gene is thought to be the main mechanism of congenital aniridia etiopathogenesis [1]. Nevertheless, true functional consequences of different types of PAX6 variants, which could include effects on splicing, are still in question. This is a reason why some aniridia associated PAX6 nucleotide variants remain outside the databases.

A previously conducted molecular genetics study of a cohort of 110 patients from 84 unrelated Russian families with a clinical diagnosis of congenital aniridia revealed six single nucleotide variants out of canonical splicing site dinucleotides, which may affect splicing: five intronic (c.142−5T>G, c.142−14C>G, c.141+4A>G, c.1032+6T>G, c.682+4delA) and one missense variants (c.140A>G) [2]. Two more PAX6 sequence variants were newly identified later: one synonymous (c.174C>T) and one deep-intronic (c.142−64A>C) (unpublished data). Among those, three variants were previously described in aniridia patients (c.140A>G [3], c.141+4A>G [4], с.1032+6T>G [5]), but without any experimental validation of the effect on the function. According to the recommendations of the American College of Medical Genetics and Genomics [6], almost all detected nucleotide variants were predicted to be pathogenic or likely pathogenic, except for the c.174C>T, c.682+4delA, and c.142−64A>C which were classified as variants of uncertain significance. In the present study, we perform functional analysis of eight PAX6 single nucleotide variants (SNVs) to evaluate their influence on the splicing pattern, which is not obvious.

Subjects and methods

A clinical and molecular genetic study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Federal State Budgetary Institution “Research Center for Medical Genetics,” Moscow, Russia, with written informed consent obtained from each participant and/or their legal representative, as appropriate. DNA samples for analysis were obtained from eight patients with a diagnosis of congenital aniridia. The clinical picture of the patients is described in Table 1. All nucleotide variants were named in accordance with the HGVS recommendations [7]. Nucleotide annotation and exons numbering were based on reference sequences NM_000280.4 and NG_008679.1. All PAX6 variants were submitted to the Leiden Open Variation Database (LOVD) (

Table 1 A summary of reported PAX6 single nucleotide variants (SNVs). Nucleotide annotation was based on reference sequences NM_000280.4 and NG_008679.1

Two vectors were used for creating the minigene reporter plasmids. Six out of eight SNVs were investigated using minigenes in pSplPIG vector kindly provided by Dr. K.A. Lukyanov. For this aim, two different genomic regions containing the exon-of-interest with the complete sequence of adjacent introns and parts of neighboring exons were cloned into the linker sequence as previously described [8] (Table S1). To introduce mutations into the wild-type minigene QuickChange Site-Directed Mutagenesis Kit was used (Agilent Technologies). Two other SNVs were investigated using the pSpl3-Flu vector, which was created by the insertion of the HIV tat intron sequence from the pSPL3 vector (a kind gift from Dr Thomas v. O. Hansen) into the linker sequence between GFP and TurboFP635 reporter genes of the pSplPIG. In each of these cases, exons-of-interest were amplified with at least 150 bp of flanking intronic sequences and cloned into the multiple cloning site within the HIV tat intron sequence as previously described [9, 10] (Table S1). Nucleotide sequences of all primers used for genomic DNA amplification and plasmid mutagenesis are presented in Table S1.

Splicing reporter plasmids were transfected into HEK293T and A375 human cell lines using Metafectene (Biontex) according to the manufacturer’s protocol. Forty-eight hours after transfection, total RNA was isolated using guanidine thiocyanate-phenol-chloroform extraction. RNA was treated with DNAseI (Thermo Scientific) and reverse transcribed using the ImProm-II™ Reverse Transcription System (Promega). To detect splicing alterations, minigene-specific cDNA was amplified with plasmid-specific primers. PCR products were separated by 12% denaturing urea polyacrylamide gel electrophoresis (urea-PAGE). Each DNA band was gel purified and sequenced with primers used for amplification.


We performed a functional analysis of two novel, three recently identified and three previously well-known SNVs of the PAX6 gene (Table 1). According to the in silico analysis with Human Splicing Finder (HSF) and IntSplice on-line tools [11, 12], seven out of eight investigated variants could influence five different splice-sites (SSs) of PAX6 pre-mRNA: (i) intron 5 donor SS (c.141+4A>G, c.140A>G); (ii) intron 5 acceptor SS (c.142−5T> G, c.142−14C>G), (iii) intron 6 donor SS (c.174C>T); (iv) intron 8 donor SS (c.682+4delA); (v) intron 11 donor SS (с.1032+6T>G). SNV c.142−64A>C could lead to the creation of an intronic ESE (exonic splicing enhancer) site and probably could not affect splicing. To determine the effects of each sequence variant on PAX6 pre-mRNA splicing we used the minigene assay, which was carried out in HEK293T and A375. The results for both cell lines were equal, indicating that observed changes were not cell-type-specific (Fig. 1).

Fig. 1

Results of minigene assay for eight PAX6 SNVs in HEK293T cell line. pSplPIG (“V1”) based reporter constructions are presented at (a) and (b), pSpl3-Flu (“V2”) based reporter constructions are presented at (c) and (d). a RT-PCR-analysis of minigene splicing for Construction 1 is aimed at investigation PAX6 nucleotide variants: c.142-5T>G, c.142-14C>G, c.174C>T, c.142-64A>C PAX6 SNVs. b RT-PCR-analysis of minigene splicing for Construction 2 is aimed at investigation PAX6 nucleotide variants: c.141+4A>G, c.140A>G. c RT-PCR-analysis of minigene splicing for Construction 3 is aimed at investigation PAX6 nucleotide variant c.682+4delA. d RT-PCR-analysis of minigene splicing for Construction 4 is aimed at investigation PAX6 nucleotide variant с.1032+6T>G. Schemes of the minigene constructions are depicted above: white boxes = PAX6 exons (with appropriate number); thick lines = PAX6 introns (full-sized for (a) and (b), partial for (c) and (d)); thin lines = plasmid-specific HIV tat intron sequence of V2; grey boxes = vector specific exons; arrows = primers used for the cDNA amplification and sequencing; asterisks = position numbers of investigated nucleotide variants. Urea-PAGE of RT-PCR fragments generated from minigene spliced RNA of wild type (WT) and mutant (MUT) constructions are shown below. Splice products are shown schematically on the right (for (a): on the right — for mutant (MUT) constructions, on the left — for wild-type (WT) constructions), oblique shade areas represent exon extension by respective number of nucleotides (nt)

Two nucleotide variants in intron 5, c.142-5T>G and c.142-14C>G, were found to lead to the creation of a novel acceptor AG dinucleotides within intron 5 and exon 6 extension by 4 and 13 nucleotides, respectively (Fig. 1a). Synonymous SNV c.174C>T resulted in the appearance of a novel intron 6 donor SS within the exon 6 and led to its shortening by 185 nucleotides (Fig. 1a). Surprisingly, we observed an additional isoform transcribed from the WT reporter construct with a shortened exon 6 (15 nt in length) (Fig. 1a). In Ensemble database release 91, we found six different isoforms of human PAX6 transcripts, which use this alternative shortened exon 6. That gives the evidence for the natural occurrence of this minor PAX6 isoform.

Analysis of sequence variants affecting intron 5 donor SS revealed that missense (c.140A>G) and intron (c.141+4A>G) variants disrupt a donor SS and lead to exon 5 skipping (Fig. 1b). Another intron variant, c.682+4delA, leads to a damage of natural donor SS of intron 8 and activation of downstream cryptic SSs. Major transcript isoform, in that case, contained exon 8 elongated by 38 nucleotides (Fig. 1c). Another major PCR-product from mutant construction corresponds to plasmid-derived cryptic SS which is not present in PAX6 pre-mRNA being an experimental artifact (Fig. 1c). Another investigated variant, с.1032+6T>G, leads to the disruption of intron 11 donor SS and exon 11 skipping (Fig. 1d).

Besides, we did not find any confirmation that variant c.142-64A>C affects splicing. This SNV was found in a proband with congenital aniridia and his mother with subtle iris hypoplasia. Further analysis of segregation of this SNV in pedigree showed proband’s grandfather carried the variant and had no signs of aniridia. The deletion affecting the PAX6 distal 3′-cis-regulatory region was found in a proband [2].


In the present study eight SNVs in the PAX6 gene, which were found in patients with congenital aniridia, were functionally characterized. We showed that all investigated variants, except for the c.142-64A>C, lead to various alterations of splicing: (i) exon skipping (c.140A>G, c.141+4A>G, с.1032+6T>G); (ii) exon extension (c.142-5T>G, c.142-14C>G, c.682+4delA); (iii) exon shortening (c.174C>T). All these alterations disrupt the open reading frame, produce a premature termination codon (PTC) and probably trigger the mRNA degradation by the nonsense-mediated decay (NMD) mechanism [13] (Fig. 2). This results in the production of a null-allele of the PAX6 gene and development of congenital aniridia through the haploinsufficiency model of pathogenesis. The severity of the aniridia phenotype in this group of patients does not differ from that in a general cohort (Table 1).

Fig. 2

Scheme of the possible pathogenic action of investigated SNVs in the PAX6 gene. Variants are listed on the left. Corresponding mRNA structures (with marked start codons, stop codons and premature stop codons (PTC)) are located next to each variant. Oblique shade areas represent exon extension by respective number of nucleotides (nt), dotted lines correspond to skipped part of mRNA. The number of nucleotides between PTC and last exon–exon junction is shown on the lower scheme (с.1032+6T>G). The possible consequences of aberrant splicing are listed on the right. NMD nonsense-mediated decay

One of the previously identified variants, c.140A>G, was described as a missense variant p.(Gln47Arg) located within the PAX6 DNA-binding paired domain (PD) and affects its function [14, 15]. In the present study, we showed that the functional effect of this SNV is a consequence of splicing disruption rather than a dysfunctional protein.

Besides, the present study is a first description of a “synonymous” SNV (c.174C>T) as a cause of congenital aniridia.

The issue of the diverse phenotypic consequences of the different functional types of PAX6 variants has been discussed for a long time, but no statistically significant correlations have been detected [16]. One reason for that might be the incorrect classification of nucleotide variants into functional categories. The functional analysis allowed us to classify seven PAX6 SNVs as loss of function variants which is very much in line with the severity of their carriers’ phenotypes.


  1. 1.

    Vasilyeva TA, Voskresenskaya AA, Khlebnikova OV, Pozdeyeva NA, Marakhonov AV, Zinchenko RA. Genetic approaches to differential diagnosis of hereditary forms of congenital aniridia. Vestn Ross Akad Med Nauk. 2017;72:233–41.

    Article  Google Scholar 

  2. 2.

    Vasilyeva TA, Voskresenskaya AA, Kasmann-Kellner B, Khlebnikova OV, Pozdeyeva NA, Bayazutdinova GM, et al. Molecular analysis of patients with aniridia in Russian Federation broadens the spectrum of PAX6 mutations. Clin Genet. 2017;92:639–44.

    CAS  Article  Google Scholar 

  3. 3.

    Prosser J, van Heyningen V. PAX6 mutations reviewed. Hum Mutat. 1998;11:93–108.

    CAS  Article  Google Scholar 

  4. 4.

    Dubey SK, Mahalaxmi N, Vijayalakshmi P, Sundaresan P. Mutational analysis and genotype-phenotype correlations in southern Indian patients with sporadic and familial aniridia. Mol Vis. 2015;21:88–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Skeens HM, Brooks BP, Holland EJ. Congenital aniridia variant: minimally abnormal irides with severe limbal stem cell deficiency. Ophthalmology. 2011;118:1260–4.

    PubMed  Google Scholar 

  6. 6.

    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

    Article  Google Scholar 

  7. 7.

    den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37:564–9.

    Article  Google Scholar 

  8. 8.

    Gurskaya NG, Staroverov DB, Zhang L, Fradkov AF, Markina NM, Pereverzev AP, et al. Analysis of alternative splicing of cassette exons at single-cell level using two fluorescent proteins. Nucleic Acids Res. 2012;40:e57.

    CAS  Article  Google Scholar 

  9. 9.

    Hansen TV, Bisgaard ML, Jonson L, Albrechtsen A, Filtenborg-Barnkob B, Eiberg H, et al. Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. BMC Med Genet. 2008;9:58.

    Article  Google Scholar 

  10. 10.

    Wang X, Zhong J, Gao Y, Ju Z, Huang JA. SNP in intron 8 of CD46 causes a novel transcript associated with mastitis in Holsteins. BMC Genom. 2014;15:630.

    Article  Google Scholar 

  11. 11.

    Shibata A, Okuno T, Rahman MA, Azuma Y, Takeda J, Masuda A, et al. IntSplice: prediction of the splicing consequences of intronic single-nucleotide variations in the human genome. J Hum Genet. 2016;61:633–40.

    CAS  Article  Google Scholar 

  12. 12.

    Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009;37:e67.

    Article  Google Scholar 

  13. 13.

    Pereverzev AP, Gurskaya NG, Ermakova GV, Kudryavtseva EI, Markina NM, Kotlobay AA, et al. Method for quantitative analysis of nonsense-mediated mRNA decay at the single cell level. Sci Rep. 2015;5:7729.

    CAS  Article  Google Scholar 

  14. 14.

    Alibes A, Nadra AD, De Masi F, Bulyk ML, Serrano L, Stricher F. Using protein design algorithms to understand the molecular basis of disease caused by protein-DNA interactions: the Pax6 example. Nucleic Acids Res. 2010;38:7422–31.

    CAS  Article  Google Scholar 

  15. 15.

    Perez-Solorzano S, Chacon-Camacho OF, Astiazaran MC, Ledesma-Gil G, Zenteno JC. PAX6 allelic heterogeneity in Mexican congenital aniridia patients: expanding the mutational spectrum with seven novel pathogenic variants. Clin Exp Ophthalmol. 2017;45:875–83.

    Article  Google Scholar 

  16. 16.

    Yokoi T, Nishina S, Fukami M, Ogata T, Hosono K, Hotta Y, et al. Genotype-phenotype correlation of PAX6 gene mutations in aniridia. Hum Genome Var. 2016;3:15052.

    CAS  Article  Google Scholar 

Download references


We appreciate and thank the patients and their families for participating in this study. We are also grateful to Galina Gening, the President of “Interregional Support Center for Patients with Aniridia “Iris” for cooperation and coordination of most patients’ efforts. This study was supported by Russian Foundation for Basic Research (RFBR) grant 17-04-00475.

Author information



Corresponding author

Correspondence to Alexandra Yu. Filatova.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Filatova, A.Y., Vasilyeva, T.A., Marakhonov, A.V. et al. Functional reassessment of PAX6 single nucleotide variants by in vitro splicing assay. Eur J Hum Genet 27, 488–493 (2019).

Download citation

Further reading